These glucose effects are amplified by non-glucose outcomes: wakefulness, motivated feeding, anti-inflammation, and neuroprotection, positioning orexin as a multi-functional therapeutic target amid the 589 million diabetes burden (International Diabetes Federation, 2025). This evidence concerns the gene HCRT and diabetes mellitus.